Cargando…
Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, (111)In or β-particle emitting, (177)Lu
BACKGROUND: Epidermal growth factor receptors (EGFR) are overexpressed on > 90% of pancreatic cancers (PnCa) and represent an attractive target for the development of novel therapies, including radioimmunotherapy (RIT). Our aim was to study RIT of subcutaneous (s.c.) PANC-1 human PnCa xenografts...
Autores principales: | Aghevlian, Sadaf, Cai, Zhongli, Hedley, David, Winnik, Mitchell A., Reilly, Raymond M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652961/ https://www.ncbi.nlm.nih.gov/pubmed/33169241 http://dx.doi.org/10.1186/s41181-020-00111-y |
Ejemplares similares
-
Dose predictions for [(177)Lu]Lu-DOTA-panitumumab F(ab′)(2) in NRG mice with HNSCC patient-derived tumour xenografts based on [(64)Cu]Cu-DOTA-panitumumab F(ab′)(2) – implications for a PET theranostic strategy
por: Ku, Anthony, et al.
Publicado: (2021) -
(111)In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin
por: Cornelissen, Bart, et al.
Publicado: (2012) -
Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [(111)In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer
por: Chan, Conrad, et al.
Publicado: (2022) -
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate (177)Lu-NNV003
por: Maaland, Astri Fjelde, et al.
Publicado: (2019) -
In vitro cytotoxicity of Auger electron-emitting [(67)Ga]Ga-trastuzumab
por: Othman, Muhamad Faiz bin, et al.
Publicado: (2020)